Icure Pharmaceutical Incorporation (KOSDAQ: 175250)

Market Cap	72.27B
Revenue (ttm)	59.84B
Net Income (ttm)	-23.89B
Shares Out	37.37M
EPS (ttm)	-635.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	247,021
Open	1,970.00
Previous Close	2,005.00
Day's Range	1,910.00 - 1,975.00
52-Week Range	1,775.00 - 3,490.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Icure Pharmaceutical Incorporation

Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides body and haircare products, including naturally derived hair and baby line, cleansing tissue, and wet wipes. Further, it offers perfumes, textile perfu...

• Industry: Perfumes, Cosmetics, and Other Toilet Preparations
• Founded: 2000
• Employees: 214
• Stock Exchange: KOSDAQ
• Ticker Symbol: 175250

Financial Performance

In 2023, Icure Pharmaceutical Incorporation's revenue was 56.81 billion, a decrease of -4.31% compared to the previous year's 59.37 billion. Losses were -31.42 billion, -24.77% less than in 2022.